share_log

6-K: Financial Report Q3 2024

6-K: Financial Report Q3 2024

6-K:2024年第三季度财务报告
美股SEC公告 ·  2024/10/29 10:23

Moomoo AI 已提取核心信息

Novartis AG has submitted its Q3 2024 Financial Report and Interim Financial Report to the Securities and Exchange Commission (SEC) on October 29, 2024, fulfilling its regulatory obligations under Form 6-K requirements.The filing was officially signed by Paul Penepent, Head of Financial Reporting and Accounting, confirming the company's compliance with the Securities Exchange Act of 1934 reporting standards for foreign private issuers.
Novartis AG has submitted its Q3 2024 Financial Report and Interim Financial Report to the Securities and Exchange Commission (SEC) on October 29, 2024, fulfilling its regulatory obligations under Form 6-K requirements.The filing was officially signed by Paul Penepent, Head of Financial Reporting and Accounting, confirming the company's compliance with the Securities Exchange Act of 1934 reporting standards for foreign private issuers.
诺华制药已于2024年10月29日向证券交易委员会(SEC)提交了2024年第三季度财务报告和中期财务报告,履行了其在6-k表格要求下的监管义务。该文件由财务报告和会计负责人Paul Penepent正式签署,确认公司符合1934年证券交易法对外国私人发行人的报告标准。
诺华制药已于2024年10月29日向证券交易委员会(SEC)提交了2024年第三季度财务报告和中期财务报告,履行了其在6-k表格要求下的监管义务。该文件由财务报告和会计负责人Paul Penepent正式签署,确认公司符合1934年证券交易法对外国私人发行人的报告标准。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
评论 评论 · 浏览 231

热点推荐

声明

本页的译文内容由软件翻译。Moomoo将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。